W

ASHINGTON — In January, it seemed like 2017 would be the year when Congress would finally take steps to rein in pharmaceutical prices. But despite President Trump’s repeated criticism of the drug industry and Democrats’ apparent willingness to work with him on the issue, no major piece of legislation has gained traction.

One legislator thinks it’s still possible: Rep. Peter Welch (D-Vt.), who sits on the House Energy & Commerce Committee, which oversees the FDA. Throughout his tenure in Washington, Welch has been outspoken on what he sees as systematic price gouging by drug makers.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.